PMH partners with LiveRaceMedia, Sheheen for 2025 live stream
Parella Motorsports Holdings (PMH) has announced changes to its live stream production for the 2025 season, partnering with LiveRaceMedia and lead announcer Ralph Sheheen to bring viewers live coverage of 20 SpeedTour events this season. With two full days of coverage each event weekend, viewers will be able to enjoy racing from the Trans Am Series presented by Pirelli (pictured above), Sportscar Vintage Racing Association (SVRA), Formula Regional Americas Championship, Formula 4 United States Championship, Ligier JS F4 Series, International GT (IGT) and Prototype Sprint Series Association presented by Hankook (PSSA).
'We're thrilled to partner with LiveRaceMedia and Ralph Sheheen to bring the fans at home coverage of SpeedTour events in 2025,' said Kim McCullough, Chief Marketing Officer of PMH. 'Ralph Sheheen has decades of experience as a broadcaster; his expertise and passion for the sport will elevate the coverage of every race. LiveRaceMedia is one of the best in the business, between showing fans the action on the track and personalities behind the helmets, we know they'll do a great job capturing SpeedTour events.'
Headquartered in Green Bay, Wis., LiveRaceMedia has covered premiere motorsport events around the world. Utilizing a variety of track, pit lane, drone and on-board cameras, LiveRaceMedia employs the most advanced broadcasting technology to bring fans coverage of the on-track action.
'We're excited to partner with SpeedTour to bring the fans at home coverage of their action-packed events in 2025,' said Brandon Rohde, Owner/CEO of LiveRaceMedia. 'We worked with them a bit last season covering events at Indianapolis Motor Speedway and New Jersey Motorsports Park. With seven owned race series, the energy and excitement during a SpeedTour weekend is off the charts. We're excited to capture that on camera and share it with motorsports fans around the world.'
Sheheen has been covering motorsports on national television for nearly 40 years. He has covered everything from Swamp Buggies to Formula 1 and from Supercross to MotoGP. Having worked with major television networks such as CBS, FOX, NBC, ESPN and more, Sheheen will become the voice of SpeedTour TV, covering 20 race weekends from coast to coast.
'I have enjoyed the SpeedTour events as a fan, and now I get the honor of being the voice of the series,' said Sheheen. 'I have a huge passion for all forms of racing and I look forward to adding to the excitement of these action-packed events. I think it is a fantastic weekend of thrilling competition from a wide variety of classes. From the thundering Trans Am machinery, both new and vintage, to a combination of open-wheel classes that are an exciting training ground for the sport's future stars, as well as the captivating SVRA classics which provide a spectacular rolling history of motorsports along with a cacophony of tremendous engine notes, SpeedTour offers something for everyone. It's going to be an awesome season and I can't wait to get started!'
SpeedTour TV's 2025 coverage kicks off with the Sebring SpeedTour, Feb. 22-23. Racing from Trans Am, SVRA, PSSA and IGT will be live both days, with the stream available on SpeedTour.TV and the SpeedTour TV YouTube channel.
Story originally appeared on Racer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21-05-2025
- Yahoo
Savara Inc. (SVRA): Analysts See 212% Upside Potential
We recently published an article titled . Savara Inc. (NASDAQ:SVRA) was one of the stocks that was covered in that article. Wall Street analysts believe SVRA has a 212% upside potential over the next 12 months. Close-up of an inhaler, representing the inhalation of the molgramostim product candidate. Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes. The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara's commitment to bringing MOLBREEVI to market as efficiently as possible. Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara's leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry. Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company's operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara's prospects, citing the company's growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%. Overall, Savara Inc. (NASDAQ:SVRA) ranks 13th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of SVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVRA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-05-2025
- Yahoo
Savara Inc. (SVRA): Analysts See 212% Upside Potential
We recently published an article titled . Savara Inc. (NASDAQ:SVRA) was one of the stocks that was covered in that article. Wall Street analysts believe SVRA has a 212% upside potential over the next 12 months. Close-up of an inhaler, representing the inhalation of the molgramostim product candidate. Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes. The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara's commitment to bringing MOLBREEVI to market as efficiently as possible. Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara's leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry. Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company's operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara's prospects, citing the company's growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%. Overall, Savara Inc. (NASDAQ:SVRA) ranks 13th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of SVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVRA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
18-03-2025
- Yahoo
Trans Am Series TA2 Toyota Camry Gets a Makeover
Expect a new look for a pair of Toyota Camrys this weekend in the Trans Am Series. Toyota Racing Development and Five Star RaceCar Bodies are taking the cover off of a new car body for the Toyota Camry at the CUBE 3 Architecture TA2 Series this weekend at Road Atlanta. The product of months-long design and development will be one display with two cars in the TA2 field—the Toyota Camrys driven by Toyota Development Driver Tyler Gonzalez in No. 10 Mobil 1 Camry for Nitro Motorsports, while Thomas Annunziata will drive the No. 90 Camry with the GR livery for Nitro Motorsports. 'We are thrilled to be able to officially unveil the Toyota Camry body for the TA2 Series,' said Jack Irving, general manager, TRD USA in a press statement. 'This body is the result of the diligent effort of so many people at TRD, Trans Am and Five Star. For us at TRD, we continue to see the value of the TA2 Series as our development drivers are able to get quality reps on iconic road courses across the country. This new body further shows the commitment Toyota has to Trans Am, now and into the future.' First-year Trans Am President Andy Lally says the Trans Am Series is excited that new Toyota is going to be part of the Trans Am Series show. "We are elated to welcome the new Toyota Camry body to the paddock in the CUBE 3 Architecture TA2 Series,' Lally said. 'The Trans Am Series prides itself as a proving ground for the future stars of stock car racing, and we've been fortunate to see many Toyota Development Drivers find success in Trans Am. We're thrilled to be able to pair their promising talents with manufacturer support in our series.' The TA2 bodies are available for purchase by teams.
